Log In
Print
BCIQ
Print
Print this Print this
 

Stivarga, regorafenib (fluoro-sorafenib) (BAY 73-4506)

Also known as: DAST Inhibitor

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionDual acting signal transduction (DAST) inhibitor of multiple kinases
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) ; Tyrosine kinase receptor 2 (Tie2)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; Tyrosine kinase receptor 2 (Tie2) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$160.0M

$160.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today